AbCellera Biologics (NASDAQ: ABCL) net income
AbCellera Biologics reported a net loss of $146.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $162.9m. Earnings per share were −$0.49.
AbCellera Biologics's best year of the last 6 was fiscal 2022. It reported a loss in 3 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$146.4m | — | −194.9% | −$0.49 |
| 2024 | −$162.9m | — | −564.8% | −$0.55 |
| 2023 | −$146.4m | −192.4% | −385.0% | −$0.51 |
| 2022 | $158.5m | +3.3% | 32.7% | $0.56 |
| 2021 | $153.5m | +29.1% | 40.9% | $0.56 |
| 2020 | $118.9m | — | 51.0% | $0.53 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
AbCellera Biologics net income compared with its sector
By net income for its latest fiscal year, AbCellera Biologics ranks 380th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of AbCellera Biologics, −194.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 378th | Charles River Laboratories | −$144.3m | −3.6% |
| 379th | Amylyx Pharmaceuticals | −$144.7m | — |
| 380th | AbCellera Biologics | −$146.4m | −194.9% |
| 381st | Caribou Biosciences | −$148.1m | −1,327.4% |
| 382nd | UroGen Pharma | −$153.5m | −139.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of AbCellera Biologics
- How much did AbCellera Biologics earn in fiscal 2025?
- AbCellera Biologics reported a net loss of $146.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $162.9m.
- What are the earnings per share of AbCellera Biologics?
- They were −$0.49 in fiscal 2025, compared with −$0.55 in fiscal 2024.
- What was the most profitable year for AbCellera Biologics?
- Of its last 6 fiscal years, fiscal 2022, with $158.5m.
- Where does AbCellera Biologics rank in its sector by net income?
- It ranks 380th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for AbCellera Biologics come from?
- From the annual report (Form 10-K) that AbCellera Biologics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that AbCellera Biologics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on AbCellera Biologics: the AbCellera Biologics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.